SpringWorks Therapeutics Revenue and Competitors

Location

#5867

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • SpringWorks Therapeutics's estimated annual revenue is currently $35M per year.(i)
  • SpringWorks Therapeutics received $103.0M in venture funding in September 2017.
  • SpringWorks Therapeutics's estimated revenue per employee is $91,864
  • SpringWorks Therapeutics's total funding is $230M.
  • SpringWorks Therapeutics's current valuation is $3.1B. (January 2022)

Employee Data

  • SpringWorks Therapeutics has 381 Employees.(i)
  • SpringWorks Therapeutics grew their employee count by 15% last year.

SpringWorks Therapeutics's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
Chief Accounting Officer (CAO)Reveal Email/Phone
3
Chief StaffReveal Email/Phone
4
CFOReveal Email/Phone
5
CEOReveal Email/Phone
6
Head Drug DiscoveryReveal Email/Phone
7
SVP, Global PharmacovigilanceReveal Email/Phone
8
Head Research And DevelopmentReveal Email/Phone
9
VP, ControllerReveal Email/Phone
10
VP, Head Clinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is SpringWorks Therapeutics?

SpringWorks Therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. Originally conceived by Pfizer, SpringWorks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. Through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. Our name is a reflection of our approach to drug development: we're springing into action to deliver treatments to people who are in great need and without alternatives.

keywords:N/A

$230M

Total Funding

381

Number of Employees

$35M

Revenue (est)

15%

Employee Growth %

$3.1B

Valuation

N/A

Accelerator

SpringWorks Therapeutics News

2022-04-20 - SpringWorks Therapeutics (NASDAQ:SWTX) Rating Lowered ...

SpringWorks Therapeutics (NASDAQ:SWTX) Rating Lowered to Sell at Zacks Investment Research. Posted by admin on Apr 28th, 2022.

2022-04-13 - SpringWorks Therapeutics Announces Clinical Trial ...

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing...

2022-04-06 - Analysts Expect SpringWorks Therapeutics, Inc. (NASDAQ ...

Analysts Expect SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Will Post Earnings of -$1.07 Per Share. Posted by admin on Apr 17th, 2022.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$111.4M381-6%N/A
#2
$47.6M3816%N/A
#3
$35M381N/AN/A
#4
$35M3819%N/A
#5
$61.9M3810%N/A

SpringWorks Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-09-26$103.0MAMultipleArticle